Q-Pharm specialises in the conduct of early phase (Phases 1 and 2) clinical trials, bioequivalence & bioavailability studies and vaccine studies. These studies are conducted in a state-of-the-art facility within the QIMR Berghofer precinct at the Royal Brisbane and Women’s Hospital, Brisbane, Australia. The company provides a comprehensive, high quality service to our clients, and conducts clinical trials in accordance with all applicable national and international standards and guidelines. Q-Pharm’s strength is its highly-qualified clinical trial team, whose leaders have a wealth of experience in clinical development. This experience enables Q-Pharm to understand the needs of our diverse range of clients and thereby deliver on time the highest quality clinical services to satisfy client needs.
Our personnel have been responsible for the management and conduct of over 350 early phase studies. The company attracts a large number of local and international clients, particularly from the United States and Europe. Q-Pharm’s facilities and experience in this sector are unrivalled in the region. The experience base includes complex early phase studies (adaptive design first-in-human studies, 3- and 4-way crossover studies, steady-state studies), very large studies (up to 120 volunteers), unconventional study designs (urinary recovery or indirect assessments via pharmacodynamic parameters), and extensive experience with food effect studies.
Therapeutic Areas: We have conducted studies using biological agents, vaccines and pharmaceutical agents using a range of delivery modalities including oral, intra-venous, sub-cutaneous, intradermal, implant, inhalation and trans-dermal routes of administration.